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Introduction {#sec1}
============

Glucose is the major source of metabolic energy for the brain. This requires that homeostatic processes maintain blood glucose concentration at a minimum of ∼5 mM to ensure sufficient provision of glucose to the brain ([@bib45]). Specialized glucose sensing cells present in peripheral locations, such as the hepatoportal vein area, and in the CNS are activated by hypoglycemia and initiate a counterregulatory response to normalize glycemia ([@bib6], [@bib12], [@bib15]). This response is mediated by activation of the autonomous nervous system and the hypothalamo-pituitary-adrenal axis, leading to the release in the bloodstream of glucagon secreted by pancreatic alpha cells, and of catecholamines and glucocorticoids secreted by the adrenal gland ([@bib46]). The combined action of these hormones promotes hepatic glucose production, lipolysis in the adipose tissue, suppression of insulin secretion, and inhibition of glucose uptake in muscle and fat. These actions restore normoglycemia and glucose flux to the brain ([@bib46]). The counterregulatory response to hypoglycemia is, thus, essential for survival.

In type 1 and type 2 diabetic patients treated with insulin, the counterregulatory response to hypoglycemia is progressively blunted causing occasional hypoglycemia. Antecedent hypoglycemic episodes then lead to a progressive loss of the hypoglycemia cognitive warning signals and to a reduced hormonal counterregulatory response. This condition, referred to as hypoglycemia associated autonomic failure (HAAF), augments the risks to develop hypoglycemic episodes of increased severity and is a major obstacle in the treatment of diabetes with insulin ([@bib8]).

Hypoglycemia detection in the brain occurs within specialized brain areas, mainly the hypothalamus and the brainstem ([@bib24], [@bib34]). These brain structures contain neuron subpopulations activated by an increase or a fall in extracellular glucose concentrations and which are referred to as glucose excited (GE) or glucose inhibited (GI) neurons, respectively ([@bib36]). Identification of these neurons is based on electrophysiological recording of their firing activity assessed in acute brain sections or using dispersed neuron populations. The molecular mechanisms of glucose sensing by GE or GI neurons are diverse ([@bib44]). Glucose sensing by GE neurons involves proteins also controlling glucose-induced insulin secretion by pancreatic beta-cells such as Glut2 ([@bib20], [@bib24]), glucokinase ([@bib21], [@bib40]), and the K~ATP~ channel ([@bib10], [@bib26]). The Na^+^/glucose co-transporters SGLT1 and SGLT3 may also contribute to glucose sensing by GE neurons ([@bib29]). On the other hand, AMP-activated protein kinase (AMPK) plays a key role in activation of GI neurons by hypoglycemia ([@bib1], [@bib25]). In contrast to AMPK and the K~ATP~ channel, which are present in all neurons, Glut2, glucokinase, and the SGLTs are present in specific, only partly overlapping neuronal subpopulations and may thus be used as markers of glucose-sensing neurons.

Identification of glucose sensing cells, in particular, those implicated in the adaptive response to hypoglycemia is of high importance to better understand the cause and possible management of HAAF. So far, the mechanisms of central glucose sensing have been explored based on the targeted analysis of genes known to be involved in glucose metabolism or signaling. Unbiased identification of genes controlling quantitative traits is, however, possible by screening genetic reference populations. The BXD recombinant inbred mice, which have been derived from the cross of DBA/2J and C57Bl6/J mice, form a particularly useful genetic reference population ([@bib2], [@bib7], [@bib32], [@bib35]). These mice have been successfully used to identify genes involved in various physiological processes such as sleep ([@bib11]), aging ([@bib13]), blood pressure ([@bib19]), or beta-cell function ([@bib48]).

Here, we aimed at identifying genes involved in the counterregulatory response by screening a BXD mouse panel for the glucagon response to 2-deoxy-D-glucose (2DG)-induced neuroglucopenia. This led to the identification of a significant QTL on the distal part of chromosome 7. To identify the causal gene in the QTL, we hypothesized that this gene should be expressed in the hypothalamus, and that its expression should correlate with the glucagon trait. Combining QTL analysis and RNA-sequencing (seq) data, we identified hypothalamic *Fgf15* as the most likely candidate gene. The functional involvement of *Fgf15* was supported by showing that: (1) it is expressed in dorsomedial hypothalamus and perifornical neurons; (2) intracerebroventricular (i.c.v.) delivery of FGF19, the human ortholog of Fgf15, reduced 2DG-induced glucagon secretion through suppression of dorsal vagal complex neuron activation, and reduction of parasympathetic nervous activity; and (3) silencing of *Fgf15* in the DMH increased 2DG-induced glucagon secretion.

Results {#sec2}
=======

Genetic and Genomic Identification of Hypothalamic Fgf15 as Regulator of Glucagon Secretion {#sec2.1}
-------------------------------------------------------------------------------------------

We searched for genomic intervals associated with glucagon secretion induced by 2DG-induced neuroglucopenia in a panel of 36 BXD mouse strains. Groups of male mice were generated for each BXD strain and used when they reached 10 weeks of age. In a first experimental session, mice were injected intraperitoneally (i.p.) with a saline solution and blood was collected 30 min later for plasma preparation and storage. Two weeks later, the mice received an i.p. injection of 2DG and blood was collected and plasma prepared. Glucagon levels were measured by radioimmunoassay at the same time for all mice and the ratio between plasma glucagon after 2DG and NaCl injections was calculated. This trait varies by 3-fold between BXD strains ([Figure 1](#fig1){ref-type="fig"}A) with the lowest response (1.5-fold) detected in BXD49 and the highest (4.7-fold) in BXD50. This trait was due to differences in stimulated plasma glucagon levels rather than to differences in basal glucagonemia ([Figure 1](#fig1){ref-type="fig"}B); it was not correlated to differences in total pancreatic glucagon content across all the BXD strains ([Figure 1](#fig1){ref-type="fig"}C). This suggests that the variability in the secretion response results from differences in hypoglycemia detection and signaling to pancreatic alpha cells rather than from differences in pancreatic glucagon stores.

Quantitative trait analysis identified a whole genome significant QTL at the distal part of the chromosome 7 ([Figure 1](#fig1){ref-type="fig"}D). The likelihood ratio statistic (LRS) peak is centered on marker rs2304086585 (LRS: 24.679; position: 151.6236 Mb) and flanked by markers c7.loc119 (position: 147.5303 Mb) and rs31652431 (position: 152.4411 Mb) ([Figure 1](#fig1){ref-type="fig"}E). This locus is ∼5 Mb wide and it contains 128 genes; it explains 49 percent of the variance of the glucagon trait.

To narrow down the genes within the QTL, which could regulate glucagon secretion, we hypothesized, first, that these must be expressed in the hypothalamus where glucose sensitive neurons are located ([@bib17], [@bib34], [@bib37]) and, second, that their level of expression must correlate with the glucagon phenotype, assuming that they are non-coding polymorphisms. We thus performed transcriptomic analysis of the hypothalamus from all the BXD strains using mice that had not undergone QTL screening to avoid a possible impact of 2DG treatment on gene expression. RNA was extracted from the hypothalamus of 3--6 mice for each strain and equal amounts of RNA from each mouse were pooled for transcript profiling by RNA sequencing analysis. We found that 65 of the 128 genes present in the Chr7 locus were expressed in the hypothalamus. The hypothalamic expression level of 11 genes was significantly correlated to the glucagon trait ([Table 1](#tbl1){ref-type="table"}). *Fgf15* mRNA was the most significantly, and negatively, correlated to the glucagon phenotype (r = -0.571; p = 2.73 × 10^-4^) ([Table 1](#tbl1){ref-type="table"}). The second gene in this table, which shows a similar high correlation with the trait as *Fgf15* is *Gm17685* (r = −0562; p = 3.58 × 10^−4^). This encodes a long non-coding RNA transcribed in reverse orientation from exon 2 of *Fgf15*, and its expression is highly correlated with that of *Fgf15* (r = 0.824; p = 6.68 × 10^−10^). The correlation with the glucagon trait of the other nine genes ([Table 1](#tbl1){ref-type="table"}) showed at least 10-fold less significant p values. Furthermore, the *Fgf15* gene of the DBA/2J and C57BL/6 mice encodes the same amino acid sequence, supporting differential expression of this gene as a possible underlying cause of the glucagon trait. We thus selected to further investigate *Fgf15* expression in the hypothalamus and its role in the response to neuroglucopenia.

Hypothalamic Fgf15 Expression, Parasympathetic Activity, and Glucagon Secretion {#sec2.2}
-------------------------------------------------------------------------------

Quantitative analysis of *Fgf15* expression in different brain nuclei showed highest expression in the hypothalamus (average cycle threshold \[CT\] of 28.7) and lower expression in the hippocampus, thalamus, and brainstem, with almost undetectable levels in the cerebellum and cortex (average CTs of 29.6, 30.1, 30.1, 34.2, and 34.5, respectively) ([Figure 2](#fig2){ref-type="fig"}A). Brain expression of *Fgf15* was, however, much lower than its expression in the ileum, its major site of expression (average CT of 21.1) ([Figure 2](#fig2){ref-type="fig"}A) ([@bib14]). Expression of the Fgf15 receptors *Fgfr1c*, *Fgfr4*, and of the co-receptor *Klotho beta* was found in all brain regions ([Figures 2](#fig2){ref-type="fig"}B--2D).

To determine the site of *Fgf15* expression, we performed in situ hybridization analysis on hypothalamic sections. As shown in [Figures 2](#fig2){ref-type="fig"}E--2I, *Fgf15* expression was found mainly in the perifornical area (PeF; [Figure 2](#fig2){ref-type="fig"}E) and the dorsomedial hypothalamus (DMH; [Figure 2](#fig2){ref-type="fig"}G). In situ hybridization using a control probe derived from a bacterial gene, *DapB*, showed no staining ([Figure 2](#fig2){ref-type="fig"}H). No *Fgf15* transcripts were detected in the dorsal vagal complex of the brainstem ([Figure 2](#fig2){ref-type="fig"}I). Detection of *Fgf15* in illeal villi is shown for comparison ([Figure 2](#fig2){ref-type="fig"}J). Finally, double in situ hybridization of *Fgf15* and of the neuronal marker *NeuN* showed that *Fgf15* was expressed in neurons ([Figures 2](#fig2){ref-type="fig"}K and 2L).

To verify that Fgf15 could regulate glucagon secretion through a central mechanism of action, we injected C57BL/6 mice i.c.v. with FGF19 (the human ortholog of Fgf15, which shows high stability in vivo and activates the same receptors; [@bib30]) or an artificial cerebrospinal fluid (aCSF). Sixty min later, the mice received an i.p. injection of saline or 2DG. The glycemia was not modified by i.c.v. injections of aCSF or FGF19 ([Figure 3](#fig3){ref-type="fig"}A; t = 0) and was similarly increased 30 min after i.p. 2DG injection in both groups of mice ([Figure 3](#fig3){ref-type="fig"}A). The plasma glucagon level in i.p. saline injected mice was unaffected by previous i.c.v. FGF19 injection ([Figure 3](#fig3){ref-type="fig"}B). However, following 2DG-induced neuroglucopenia, the glucagon response was markedly lower in mice previously treated with i.c.v. FGF19 ([Figure 3](#fig3){ref-type="fig"}B). In these experiments, secretion of insulin, corticosterone, and epinephrine 30 min after i.p. saline or 2DG injections was not affected by previous i.c.v. FGF19 injection ([Figures 3](#fig3){ref-type="fig"}C--3E).

Next, we assessed hypothalamic *Fgf15* expression and 2DG-induced glucagon secretion in normal chow (NC) or high fat diet (HFD) fed mice, which show altered glucagon plasma levels ([@bib5]). Mice fed a HFD for 4 weeks showed increased hypothalamic expression of *Fgf15* compared to NC fed mice ([Figure 3](#fig3){ref-type="fig"}F). When injected with 2DG, NC and HFD mice showed the same hyperglycemic response ([Figure 3](#fig3){ref-type="fig"}G). The basal glucagonemia of both groups of mice were the same, but the plasma glucagon response to 2DG was markedly reduced in HFD fed mice ([Figure 3](#fig3){ref-type="fig"}H). Thus, HFD feeding increased hypothalamic *Fgf15* expression and is correlated with reduced neuroglucopenia-induced glucagon secretion in agreement with the results of the genetic screen.

To more directly determine whether the level of expression of *Fgf15* in the hypothalamus regulates glucagon secretion, we developed recombinant lentiviruses to express a control or an *Fgf15*-specific short hairpin (sh)RNA. Three shRNAs were designed to target the *Fgf15* sequence and were subcloned in lentiviral vectors. These were first tested in HEK293T cells co-transfected with an *Fgf15-GFP* expression plasmid. One vector induced efficient silencing of *Fgf15* mRNA and protein expression ([Figures 4](#fig4){ref-type="fig"}A--4C). This was used to generate a recombinant lentivirus, which effectively silenced Fgf15 expression in transduction experiments ([Figure 4](#fig4){ref-type="fig"}D). This or a control lentivirus was then injected bilaterally in the DMH ([Figure 4](#fig4){ref-type="fig"}E). Two weeks later, the mice were injected i.p. with 2DG and plasma glucagon was measured 30 min later. The mice were then killed to verify the sites of virus injection. No difference in basal glycemia or in glycemic response to 2DG injection was observed between the two groups of mice ([Figure 4](#fig4){ref-type="fig"}F). However, neuroglucopenia-induced glucagon secretion was significantly increased (22%) in mice with correct bilateral DMH injection of the silencing lentivirus as compared to mice injected with the control lentivirus ([Figure 4](#fig4){ref-type="fig"}G) or mice injected with *Fgf15*-specific shRNA lentivirus outside of the DMH ([Figure 4](#fig4){ref-type="fig"}G, "missed"). Bilateral injection of the silencing lentivirus in the PeF ([Figure 4](#fig4){ref-type="fig"}H) did not impact glycemia before and 30 min after i.p. 2DG ([Figure 4](#fig4){ref-type="fig"}I), nor the neuroglucopenia-induced glucagon secretion ([Figure 4](#fig4){ref-type="fig"}H). Taken together, these data show that *Fgf15* expression by DMH neurons has a negative impact on neuroglucopenia-induced glucagon secretion.

Glucagon secretion during hypoglycemia is triggered by the activation of both parasympathetic and sympathetic branches of the autonomic nervous system (ANS) ([@bib42]). As i.c.v. FGF19 decreased the glucagon response to 2DG-induced neuroglucopenia, but had no effect in non-injected or i.p. saline injected mice, we measured sympathetic and parasympathetic nerve activities in response to i.p. 2DG in mice, which had previously received i.c.v. aCSF or FGF19. Parasympathetic nerve activity showed no differences between groups in the basal state ([Figure 5](#fig5){ref-type="fig"}A). After 2DG injection, its activity increased 2-fold in mice pre-treated with aCSF, but remained unchanged in mice pre-treated with FGF19 ([Figure 5](#fig5){ref-type="fig"}A). Sympathetic nerve activity showed no differences between the groups in the basal state or following 2DG injections ([Figure 5](#fig5){ref-type="fig"}B). Thus, i.c.v. injection of FGF19 inhibits 2DG-induced parasympathetic, but not sympathetic nervous activity.

The dorsal motor nucleus of the vagus (DMNX) is formed by the soma of the vagal neurons and is controlled by inputs from several brainstem and hypothalamic nuclei ([@bib3], [@bib41]). To investigate whether FGF19 influences these neurons directly or indirectly, we quantified the number of pERK1/2 (activated by FGF19 binding to its receptor) positive cells in the hypothalamus and the brainstem 30 min after i.c.v. aCSF or FGF19 injections. We observed an increased number of pERK1/2 positive cells in the arcuate nucleus (ARC) after i.c.v. FGF19 injection ([Figures 5](#fig5){ref-type="fig"}C and 5D). No increase in pERK1/2 positive cells was observed in other hypothalamic nuclei, in the dorsal vagal complex (DVC, which comprises the DMNX, the nucleus tractus solitarius \[NTS\], and the area postrema \[AP\]), nor in other brainstem areas. These results are consistent with a previous study ([@bib23]) and suggest that the primary neurons involved in the effect of FGF19 are located within the ARC.

To determine whether FGF19 could control vagal neurons of the DVC in an indirect manner, we injected mice i.c.v. with aCSF or FGF19 and 1 hr later i.p. with NaCl or 2DG. Thirty min later, the mice were killed and brain sections prepared for *c-fos* expression analysis by in situ hybridization. [Figures 5](#fig5){ref-type="fig"}E and 5F show that i.p. 2DG induced a strong increase in *c-fos* expression in the NTS and the DMNX. However, in mice, which had previously received FGF19, 2DG-induced *c-fos* expression was markedly lower in both structures.

These data further support a role for central Fgf15 in modulating the sensitivity of the DVC to 2DG-induced neuroglucopenia and in reducing the stimulation of vagal activity. They also support a role of Fgf15 neurons in controlling the DVC through an indirect mechanism that first controls arcuate neurons activity.

Discussion {#sec3}
==========

The present unbiased approach identified hypothalamic *Fgf15* as a negative regulator of glucagon secretion in response to neuroglucopenia. In situ hybridization revealed that *Fgf15* is expressed by a subgroup of neurons of the DMH and PeF. Physiological studies showed that i.c.v. injection of FGF19 reduced, whereas shRNA mediated silencing of *Fgf15* in the DMH increased neuroglucopenia-induced glucagon secretion. Furthermore, i.c.v. delivery of FGF19 prevented the increase in vagal activity induced by neuroglucopenia, and this was associated with a reduced activation of DVC neurons. As i.c.v. FGF19 activates pERK1/2 only in hypothalamic ARC neurons, our data suggest that hypothalamic Fgf15 modulates DVC activity in an indirect manner.

Fgf15/19 belongs to the endocrine fibroblast growth factor family, which also includes Fgf21 and Fgf23 ([@bib30]). Fgf15/19 expression in ileal cells is induced by the bile acids released in the intestinal lumen in the postprandial state through activation of the bile acid nuclear receptor FXR ([@bib14]). Fgf15/19 binds to receptors consisting of Fgfr1c or Fgfr4 and the co-receptor klotho-beta ([@bib30]). In liver, Ffg15/19 reduces bile acid synthesis through the inhibition of Cyp7a1 ([@bib16], [@bib47]). It also induces glycogen synthesis through the activation of the Ras-Erk-p90RSK and inhibits gluconeogenesis via the CREB-PGC1α pathway ([@bib18], [@bib33]). Ffg15/19 has more recently been described to affect body weight, glucose tolerance, and insulin sensitivity through a central action ([@bib23], [@bib27], [@bib38]).

Here, we found that *Fgf15* is also expressed in the hypothalamus through an unbiased search for genetic intervals associated with neuroglucopenia-induced glucagon secretion in recombinant inbred mice. Among the 128 genes present in the identified QTL of chromosome 7, RNA-seq analysis revealed that 11 of these genes were expressed in the hypothalamus and expression of *Fgf15*, and, of the large intergenic noncoding RNA (linc)RNA-encoding, *Gm17685* showed the highest correlation with the glucagon trait. Expression levels of *Fgf15* and *Gm17685* were also highly positively correlated to each other. As lincRNAs are implicated in the control of gene expression through a variety of mechanisms ([@bib49]), it could be hypothesized that *Gm17685* plays a regulatory role in *Fgf15* expression. Testing this will, however, require future investigations.

To localize *Fgf15* expression in the brain, we used a highly sensitive and specific in situ hybridization technique. In the hypothalamus, expression of *Fgf15* was found in the PeF and in the DMH, and co-in situ hybridization analysis with the neuronal marker *NeuN* revealed that it was expressed in neurons. No signal for F*gf15* was identified in the DVC or in any other brainstem nuclei.

To assess whether central Fgf15 could impact neuroglucopenia-induced glucagon secretion, we first injected i.c.v. FGF19 in C57BL/6 mice and tested the glucagon response to a subsequent i.p. injection of 2DG. We observed that i.c.v. FGF19 decreased the glucagon response induced by 2DG, in agreement with the results of the genetic screen. We also observed in a model of high fat diet feeding an association between overexpression of hypothalamic *Fgf15* and a decrease in 2DG-induced glucagon secretion, lending further support to the negative correlation between hypothalamic Fgf15 and glucagon secretion. However, the most convincing evidence for a direct link between hypothalamic *Fgf15* expression and glucagon secretion comes for the shRNA-mediated silencing of *Fgf15*. This effect was observed when injection of the recombinant lentivirus was in the DMH, but not in the PeF. Because the PeF is a rather large structure, it is possible that our injections were not sufficiently extensive over the entire PeF structure to observe an effect. Nevertheless, the critical observation is that injection of the recombinant lentivirus in the DMH was sufficient to increase 2DG-induced glucagon secretion, establishing a direct link between *Fgf15* in this structure and the control of glucagon secretion.

Other studies have shown that i.c.v. FGF19 could improve glucose tolerance in HFD fed mice and ob/ob mice ([@bib23], [@bib27]). In ob/ob mice, the effect of FGF19 on glucose tolerance was associated with an increase in insulin-independent glucose disposal and insulin sensitivity without changes in insulin secretion. Glucagon secretion was, however, only assessed following i.p. injection of FGF19 and was not modified by this treatment ([@bib27]).

Neuroglucopenia-induced glucagon secretion involves activation of the parasympathetic and sympathetic branches of the autonomic nervous system. During graded hypoglycemia development, the parasympathetic nerve is activated immediately when the glycemia falls under the ∼5 mM and sympathetic activity is increased at lower glycemic levels ([@bib42]). Here, we found that i.c.v. FGF19 dampens parasympathetic, but not sympathetic nerve activity during 2DG-induced neuroglucopenia, an observation that provides an explanation for the reduced glucagon secretion. Moreover, the observation that 2DG-induced-glucagon secretion was not completely blunted after i.c.v. FGF19 can be explained by the fact that the sympathetic activity was not affected by i.c.v. FGF19. This suggests that FGF19 specifically impairs the parasympathetic activity to reduce glucagon secretion during neuroglucopenia.

The soma of the parasympathetic neurons is located within the DVC. The primary neurons activated by i.c.v. FGF19 and identified by immunofluorescence detection of pERK1/2 are, however, present in the ARC and not found in other hypothalamic or brainstem nuclei. This is in agreement with previous observations showing that FGF19 activates pERK1/2 in the ARC ([@bib23]). Importantly, we found that i.c.v. FGF19 blunted 2DG-induced neuronal activation in the NTS and the DMNX as assessed by *c-fos* expression analysis. This therefore indicates that i.c.v. FGF19 can prevent activation of DVC neurons in response to neuroglucopenia, and our observations suggest that its action may be indirect through a first action on ARC neurons. This also provides an explanation for the dampening effect of i.c.v. FGF19 on neuroglucopenia-induced vagal activity.

Previous reports have shown that i.c.v. FGF19 induces pERK1/2 in NPY/AgRP neurons, but fails to induce c-*fos* in POMC neurons ([@bib23], [@bib27]). Thus, NPY/AgRP neurons could be the primary target neurons of Fgf15 neurons of PeF and/or DMH, and these neurons may then negatively control DVC neurons in a pERK1/2-dependent manner. A role for the ARC and NPY/AgRP neurons in mediating the effects of Fgf15/19 can be supported by the fact that the melanocortin pathway has been shown to be necessary for the central effects of FGF19 on glucose tolerance ([@bib23], [@bib27]). Whereas tracing approaches in mice expressing the Cre recombinase under the control of *Fgf15* promoter should be used to confirm these observations, our data provide a first insight in a *Fgf15*-dependent neural network, which involves an ARC/DVC pathway to regulate glucagon secretion during neuroglucopenia.

Together, our genetic screen combined with gene expression analysis provides compelling evidence that hypothalamic *Fgf15* is negatively involved in the control by neuroglucopenia of glucagon secretion. *Fgf15* is expressed by discrete subpopulations of neurons in the PeF and DMH and Fgf15/19 blunts vagal firing activity and dampens the response of the DVC neurons to 2DG-induced neuroglucopenia, a response that involves activation of pERK1/2 in ARC neurons. Collectively, these results, initiated by an unbiased search for novel genes involved in counterregulatory response to neuroglucopenia, reveal a new site of *Fgf15* expression and provide a mechanistic framework to elucidate Fgf15 action in the control of parasympathetic nervous activity and glucagon secretion. They may provide new insight into the neuronal control of counterregulation and its deregulation in the etiology of HAAF in type 1 and type 2 diabetic patients.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

BXD mouse strains were purchased from the center of phenogenomics of EPFL (Lausanne). C57Bl6/J mice were purchased from Charles River Laboratories. Animals were housed on a 12 hr light/dark cycle and were fed a standard rodent chow diet (Diet 3436, Provimi Kliba) or a high-fat diet (235 HF, SAFE diets). Experiments were performed with 10- to 14-week-old male mice.

Study Approval {#sec4.2}
--------------

All animal experimentations were approved by the Veterinary Office of Canton de Vaud.

Biochemical Measurements {#sec4.3}
------------------------

Blood was collected under isoflurane anesthesia. Glycemia was measured using a glucometer (Ascensia Breeze 2, Bayer Healthcare). Glucagon was quantitated by radioimmunoassay (Millipore, cat. number: GL-32K). ELISAs were used for insulin (cat. number: 10-1247-10, Mercodia), and corticosterone (cat. number: ADI-900-097, Enzo Life Sciences) measurements. Free plasma epinephrine was quantified as described ([@bib9]).

Phenotyping of Glucagon Secretion in BXD Mice {#sec4.4}
---------------------------------------------

BXD mice were handled daily for 2 weeks before the experiment. On the first experiment day, glycemia was taken at 9:00 a.m. and, if stable for 1 hr, the mice received at 10:00 am an i.p. injection of NaCl 0.9%. Blood was collected 30 min later for basal glucagon quantification. Mice were then allowed to recover for 2 weeks with daily handling. Then the same protocol was used with i.p. injection of 2DG (600 mg/kg).

RNA-Seq Analysis {#sec4.5}
----------------

Total RNA extraction from hypothalamus and brainstem samples was performed using the peqGOLD TriFast method (PEQLAB). RNA were obtained from mice sacrificed during the morning in random fed conditions as for the QTL screening. RNA integrity was verified with a 2100 Bioanalyser (Agilent). For each BXD strain, equal amounts of RNAs from 3 to 6 hypothalami were pooled in a final volume of 50 μL. RNA-seq libraries were prepared using 1 μg of pooled RNAs and the Illumina TruSeq Stranded mRNA reagents (Illumina) on a Sciclone liquid handling robot (PerkinElmer) using a PerkinElmer-developed automated script. Cluster generation was performed with the resulting libraries using the Illumina TruSeq SR Cluster Kit v3 reagents and sequenced on the Illumina HiSeq 2000 using TruSeq SBS Kit v3 reagents. Sequencing data were processed using the Illumina Pipeline Software version 1.82. A sequencing depth of 40 millions of reads using 100 bp single-end reads was used. Reads were mapped to the *mm9* genome with tophat (v. 2.0.8) using library-type = fr-firststrand. Other parameters were set by default. Count data for exons were generated using htseq-count from the HTSeq package (<http://www.huber.embl.de/users/anders/HTSeq/>, version 0.5.4p3) using RefSeq annotation, with parameters stranded = reverse and mode = union. The normalized read counts per gene were log transformed, and then Pearson correlation was used to calculate the correlation of gene expression with the physiological trait.

QTL Mapping {#sec4.6}
-----------

GeneNetwork ([www.genenetwork.org](http://www.genenetwork.org){#intref0015}) variants data set comprising about 15,000 SNPs on the whole mouse genome was used to perform QTL mapping. Calling SNPs on our RNA-seq data have been used as a way to check for genetic drift in the BXD strains. SNP calling was performed using the Genome Analysis ToolKit from the Broad Institute (v. 3.2) using the recommended workflow for RNA-seq data. Variants were filtered using a quality threshold (\> = 5,000). Furthermore, genotypes with more than 10% missing information were also removed. This allowed tagging the discrepant variants---compared to our RNASeq experiments---as "unknown" (eight 0.05% genotypes per strain) for QTL analysis. Finally, variants similar to our SNP calling data were merged to remove redundant information. For QTL analysis, we used the r/qtl packages with Haley-Knott (HK) regression method. Pseudo-markers were generated at a density of 1 cM. QTL location was obtained with 1.5 LOD (6.915 LRS) support intervals as suggested previously ([@bib4]). The significance and suggestive thresholds were computed with 2,000 permutations: the sequences of the various strains were shuffled 2,000 times and association recalculated at each permutation. This allowed calculating the probability to find these associations by chance.

shRNA Selection and Lentivirus Production {#sec4.7}
-----------------------------------------

To test the efficiency of the *Fgf15* shRNAs, an Fgf15 cDNA was subcloned in frame with GFP in the pCMV6-AC-GFP plasmid (cat. number: MG202456, OriGene) and scrambled or *Fgf15*-targeted shRNAs were subloned in the pGFP-C-shLenti plasmid (cat. number: TL514099, OriGene). The vectors were co-transfected into HEK293T cells using lipofectamine 3000 (cat. number: L3000015, Thermo Fisher Scientific). At 48 hr later, total RNA and proteins were extracted and *Fgf15* expression was determined by qRT-PCR and protein by western blot. The selected shRNA sequence has the following sequence: 5′-GTCTGTGTCAGATGAAGATCCACTCTTTC-3′. Lentiviruses were produced as described ([@bib39]). Viral titers were evaluated by infection of HEK293T cells. The silencing efficacy of the *Fgf15*-shRNA lentivirus was tested in infected HEK293T cells that were transfected with Fgf15 expression plasmid.

Stereotaxy {#sec4.8}
----------

Surgeries were performed under ketamine/xylazine anesthesia. Cannulas were placed in the lateral ventricle (−0.7 mm from the bregma; −1.3 mm from the midline; and −1.8 mm from the surface of the skull) ([@bib31]). Lentiviruses (200 nL; 4.10^9^ TU/mL) were injected in the DMH (−1.7 mm from the bregma; ± 0.35 mm from the midline; and −5.0 mm from the surface of the skull) and PeF (−1.7 mm from the bregma; ± 0.75 mm from the midline; and −5.15 mm from the surface of the skull) ([@bib31]). Animals were allowed to recover for 1 week with daily handling and body weight monitoring after i.c.v. placement and for 2 weeks after lentivirus injections. The placement of the cannula was checked by histological analysis after blue ink delivery, and the sites of injection (GFP fluorescence) were verified on 40 μm brain sections.

I.c.v. Injections {#sec4.9}
-----------------

Mice received at 9:00 am on the test day either i.c.v. aCSF (125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 26 mM NaHCO3 and 12.5 mM sucrose, 300 mOsm, and pH = 7.4) or FGF19 (2.5 μg) (cat. number: cyt-700-b, Prospecbio). One hr later, mice were injected i.p. with NaCl 0.9% or 2DG 600 mg/kg. Blood and brains were collected 30 min later for quantification of glucagon secretion or for in situ hybridization detection of *c-fos*. For pERK1/2 detection, brains were dissected 30 min after i.c.v. delivery of either aCSF or FGF19.

qRT-PCR {#sec4.10}
-------

Tissues preparation, RNA extraction, and qRT-PCR were performed as described ([@bib28]). The following forward (F) and reverse (R) primers were used: fibroblast growth factor 15 (*Fgf15*) F5′-GAGGACCAAAACGAACGAAATT-3′ and R5′-ACGTCCTTGATGGCAATCG-3′; fibroblast growth receptor 1 isoform c (*Fgfr1c*): F5′-GGAGGTGCTTCATCTACGGA-3′and R5′-AGAGTGATGGGAGAGTCCGA-3′; fibroblast growth receptor 4 (*Fgfr4*): F5′-GCCCGACAGTTCTCTTTGGA-3′ and R5′- TTCCCAAAGCGGATCGAGAG-3′; klotho beta (*Klotho beta*): F5′-CCTTCCCACTGGCAATCTGT-3′and R5′-GGGTGGTACAACGTCACCAT-3′; and beta-glucuronidase (*Gusb*): F5′-GTGATGGAGGAGCTGGTTCG-3′ and R5′-AGCAGAGGAAGGCTCATTGG-3′. *Gusb* was used as a housekeeping gene to normalize gene expression in all experiments.

Immunofluorescence Microscopy and In Situ Hybridization {#sec4.11}
-------------------------------------------------------

For immunofluorescence detection of pERK1/2, mice were fixed by a transcardiac perfusion of 4% cold paraformaldehyde (PFA) in sodium phosphate buffer (0.1 M, pH 7.4). Brains were dissected and kept for 2 hr in PFA at 4°C before overnight incubation in sucrose 30% at 4°C and frozen at −80°C. There were 20 μm cryosections that were prepared, placed on glass slides, and incubated in a blocking buffer consisting of 0.1 M phosphate buffer pH 7.4 containing 3% of normal goat serum and 0.3% Triton X-100 for 1 hr, then with a rabbit monoclonal antibody directed against pERK1/2 (cat. number: 4370, 1/200, Cell Signaling) for 48 hr, and for 1.5 hr with an Alexa Fluor 488-conjugated goat anti-rabbit IgG (H+L) antibody (cat. number: 11008, 1/400, Life Technologies). Slides were mounted in Mowiol for fluorescence imaging. For pERK1/2 positive cells quantification, four different sections for each mouse were analyzed. For in situ hybridization analysis, the hypothalamus and brainstem were dissected using a mouse brain matrix with 1-mm section dividers (CellPoint Scientific); all tissues were fixed for 28 hr in 10% formalin before embedding in paraffin. There were 5 μm sections that were cut and in situ hybridization for *Fgf15*, *c-fos*, *NeuN*, and dihydrodipicolinate reductase (*DapB*) (cat. number: 412811, 316921, 313311, and 310043) was processed using the RNAscope and RNAscope 2.0 HD Red Detection Kit Assay (Advanced Cell Diagnostics). Double in situ hybridization was performed using RNAscope 2-Plex Assay (cat. number: 320701). Sections were counterstained with Mayer's hematoxylin, mounted using Aquatex mounting medium (cat. number: 363123S, VWR), and observed using an Axio Imager D1 (Zeiss) microscope interfaced with AxioVision software (Zeiss). Quantification of *c-fos* expression was performed on sections cut at bregma −7.56 mm from three different mice. Image analysis was performed using ImageJ.

Autonomic Nervous System Activity Recording {#sec4.12}
-------------------------------------------

The firing rates of the thoracic branch of both vagal and sympathetic nerves along the carotid artery were recorded as previously described ([@bib22], [@bib43]). Unipolar nerve activity was recorded continuously for 1 hr under isoflurane anesthesia (30 min during basal condition after i.c.v. aCSF/FGF19 and before i.p. 2DG and 30 min during 2DG-induced neuroglucopenia) using the LabChart 8 software (AD Instrument). Data were digitized with PowerLab 16/35 (ADInstruments). Signals were amplified 10^5^ times and filtered using 200/1,000 Hz band pass filter. Firing rate analysis was performed using LabChart 8.

Statistical Analysis {#sec4.13}
--------------------

Data are expressed as mean ± SEM. Statistical analysis were performed using GraphPad Prism 5.0c, either by a one-way Anova followed by Bonferroni post hoc test, a two-way Anova followed by Bonferroni post hoc test, or by an unpaired two-tailed Student's t test when appropriate. p values less than 0.05 were considered significant.
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![A Locus on Chromosome 7 Controls Neuroglucopenia-Induced Glucagon Secretion\
(A) Distribution of the glucagon ratio (2DG/NaCl) phenotype in the 36 BXD strains (n = 4--14 for each strain).\
(B) Basal and neuroglucopenia-stimulated glucagonemia in the 36 BXD mouse strains. Each circle is the mean glucagonemia for each strain.\
(C) Scatterplot representing the absence of correlation between the glucagon ratio (2DG/NaCl) phenotype and the total pancreatic glucagon content in BXD mice.\
(D) Whole genome significant QTL on distal chromosome 7. The red line indicates the whole genome significative threshold (p ≤ 0.05). The blue line indicates the whole genome suggestive threshold (p ≤ 0.63).\
(E) Localization of the locus between with a LRS peak on marker rs2304086585.](gr1){#fig1}

![*Fgf15* Expression in Adult CNS\
(A--D) Expression level of *Fgf15*, *Fgfr1c*, *Fgfr4*, and *Klotho beta* in different brain structures and the ileum (n = 6--8). hypothalamus, Hy; hippocampus, Hip; thalamus, Th; cerebellum, Cb; brainstem, Bs; cortex, Cx; ileum, Il.\
(E--J) In situ hybridization detection of *Fgf15* (red signal).\
(E--J) PeF; representative section of hypothalamus at bregma −1.94 mm (F); DMH (G); negative control in PeF using *DapB* probes (H); brainstem with central canal (CC) DMNX and nucleus of the solitary tract (NTS) (I); and illeal villi (J). The scale bar represents 50 μm.\
(K and L) Double in situ hybridization of *Fgf15* (green dots) and *NeuN* (red dots) in PeF and DMH showing neuronal expression of *Fgf15*. The scale bar represents 10 μm. The data are shown as mean ± SEM.](gr2){#fig2}

![Fgf19 and the Control of Glucagon Secretion\
(A) Glycemia of mice injected i.c.v. with aCSF or FGF19 60 min before i.p. injection (0 min) of 2DG (600 mg/kg) (n = 7).\
(B) Plasma glucagon 30 min after i.p. injection of saline or 2DG in mice that were treated 60 min before with i.c.v. injection of aCSF or FGF19 (n = 7).\
(C--E) Plasma insulin (C), corticosterone (D), and epinephrine (E) 30 min after i.p. injection of saline or 2DG in mice that were treated 60 min before with i.c.v. injection of aCSF or FGF19 (n = 9--10) (E).\
(F) Hypothalamic expression of *Fgf15* in C57Bl6/J mice fed a NC or a HFD for 4 weeks (n = 6--8).\
(G) Glycemia in NC and HFD fed mice before and 30 min after i.p. injection of 2DG (n = 6--8).\
(H) Plasma glucagon in NC and HFD fed mice in the basal state and 30 min after 2DG injection (n = 6--8).\
Data are mean ± SEM. ^∗^p ≤ 0.05 and ^∗∗∗^p ≤ 0.001. Two-way ANOVA followed by Bonferroni post hoc test (A--E, G, and H). Student's t test (F).](gr3){#fig3}

![*Fgf15* Silencing in the DMH Increases 2DG-Induced Glucagon Secretion\
(A) Silencing of *Fgf15* expression after co-transfection of HEK293T cells of an *Fg15-GFP* cDNA with the selected *Fgf15*-specific shRNA encoding lentiviral vector (n = 3).\
(B) Quantification of Fgf15 protein expression in the same conditions as (A) (n = 3).\
(C) Western blot analysis of Fgf15 and β-actin expression quantitated in (B).\
(D) Western blot analysis of Fgf15 and β-actin expression in HEK293T cells infected with a control (scrambled) or an *Fgf15*-shRNA lentivirus and transfected with an *Fgf15-GFP* expression plasmid.\
(E) Example of the correct bilateral injection in the DMH of *Fgf15*-shRNA lentiviruses. The scale bar represents 100 μm.\
(F) Glycemia in mice injected in the DMH with control (scrambled) or *Fgf15*-shRNA lentiviruses before (0 min) and 30 min after i.p. injection of 2DG. missed: mice with incorrect *Fgf15*-shRNA encoding lentivirus injection sites. (n = 10--19).\
(G) Plasma glucagon levels 30 min after 2DG i.p. injections (n = 10--19).\
(H) Example of the correct bilateral injection in the PeF of *Fgf15*-shRNA lentiviruses. The scale bar represents 100 μm.\
(I) Glycemia in mice injected in the PeF with control (scrambled) or *Fgf15*-shRNA lentiviruses before and 30 min after i.p. injection of 2DG (n = 12).\
(J) Plasma glucagon levels 30 min after 2DG i.p. injections (n = 12).\
Data are mean ± SEM. ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; and ^∗∗∗^p ≤ 0.001. Student's t test (A, B, and J). Two-way ANOVA followed by Bonferroni post hoc test (F and I). One-way ANOVA followed by Bonferroni post hoc test (G).](gr4){#fig4}

![FGF19 Blunts 2DG-Induced Parasympathetic Nerve Activity\
(A) Parasympathetic nerve firing rate in the basal state and following i.p. 2DG injection in mice previously treated with i.c.v. aCSF or FGF19 (top: representative trace and bottom: quantification of the firing activity) (n = 6--7).\
(B) Sympathetic nerve firing rate in the basal state and following i.p. 2DG injection in mice previously treated with i.c.v. aCSF or FGF19 (top: representative trace and bottom: quantification of the firing activity) (n = 7).\
(C) Representative micrographs of pERK1/2 positive cells in the ARC 30 min after i.c.v. injection of aCSF or FGF19.\
(D) Quantification of pERK1/2 positive cells in the ARC 30 min after i.c.v. injection of aCSF or FGF19. (n = 5--7).\
(E) Representative micrographs of *c-fos* positive cells in NTS and DMNX at bregma −7.56 mm of mice that received i.c.v. aCSF and 60 min later i.p. NaCl (upper), i.c.v. aCSF and 60 min later i.p. 2DG (mid), or i.c.v FGF19 and 60 in later i.p. 2DG (lower). area postrema, AP; central canal, CC; nucleus of the solitary tract, NTS; DMNX.\
(F) Quantification of *c-fos* positive cells in NTS and DMNX of mice treated as in (E). The scale bar represents 50 μm.\
Two-way ANOVA followed by Bonferroni post hoc test (A and B). Student's t test (D). One-way ANOVA followed by Bonferroni post hoc test (F). ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; and ^∗∗∗^p ≤ 0.001.\
Data are mean ± SEM.](gr5){#fig5}

###### 

QTL Genes Expressed in the Hypothalamus and Correlated with the Glucagon Trait

  Gene[a](#tblfn1){ref-type="table-fn"}   Start        Strand   Length   Gene ID   NM ID          r[b](#tblfn2){ref-type="table-fn"}   p Value[c](#tblfn3){ref-type="table-fn"}
  --------------------------------------- ------------ -------- -------- --------- -------------- ------------------------------------ ------------------------------------------
  Fgf15                                   152.082436   \+       4.42     14170     NM_008003      −0.571                               2.73 × 10^−4^
  Gm17685                                 152.080465   −        2.902    NA                       −0.562                               3.58 × 10^−4^
  Ccnd1                                   152.115835   \+       9.995    12443     NM_007631      0.472                                0.00369
  Ppfia1                                  151.66266    −        76.975   233977    NM_001195086   0.457                                0.00509
  Dhcr7                                   151.009071   −        25.244   13360     NM_007856      −0.456                               0.00520
  Cttn                                    151.621628   −        35.018   13043     NM_007803      0.440                                0.00726
  Kcnq1ot1                                150.399016   −        83.437   63830     AK041889       −0.415                               0.0119
  Slc22a18                                150.659659   \+       25.578   18400     NM_001042760   −0.401                               0.0153
  Lrdd                                    148.624413   −        4.841    57913     NM_022654      −0.379                               0.0228
  Ifitm1                                  148.153327   \+       2.399    68713     NM_001112715   −0.332                               0.0482
  Tmem80                                  148.514028   −        9.026    71448     NM_027797      0.331                                0.0488

Genes are listed according to the p value of the correlation between gene expression and the glucagon trait.

r: Pearson's correlation coefficient between gene expression and the glucagon trait.

p value: p value of the Pearson's correlation between gene expression and the glucagon trait.

[^1]: Lead Contact
